Biotechnology

In the race for a 'longevity protein' therapy, a key safety milestone is met. This de-risks the path to the clinic, but what does it mean for the future?

Biodexa nets $2.3M in a complex warrant deal, buying runway for its cancer and diabetes drugs at the steep price of massive potential shareholder dilution.

Imvax has promising data and a clear regulatory path for its glioblastoma therapy. Now it faces the ultimate test: raising millions to fund the final push.

FDA Fast Track for Kestrel's KST-6051 signals more than just a new drug; it reveals a new strategy in the war on cancer, backed by Big Pharma's billions.

A late-stage biotech is betting on a novel idea: what if we could repair eye damage at a structural level? Stuart Therapeutics' PolyCol™ platform aims to do just that.

Axiom Biosciences' pact with CDMO GeneFab isn't just a deal; it's a strategic necessity to scale its promising therapies from the lab to patients.

TOLREMO's successful Phase I trial for TT125-802 validates a novel strategy against NSCLC, offering new hope by targeting cancer's clever escape routes.

Xylo Bio's new drug for depression enters trials, betting it can rewire the brain without the hallucinogenic burden. Is this the future of mental healthcare?

BIOHK2026 reveals Hong Kong's operational blueprint for a global biotech hub, leveraging a landmark CITIC partnership and deep Greater Bay Area integration.

Beyond predicting structures, MoleculeMind's QuantaMind simulates entire chemical reactions, offering a dynamic view that could slash R&D costs in pharma.

A cancer diagnostics firm is acquiring a robotics company. A new $2.5M loan shows how serious the gamble is, revealing a story of high risk and high-tech ambition.

A small biotech assembles top experts to guide a promising, Sanofi-licensed drug through trials, betting it can solve a stubborn cardiovascular challenge.

With impressive Phase 2 data, Revelyx Bio's ready-to-use recombinant toxin YY003 signals a major technological and practical shift for the aesthetics industry.

As pharma giants dominate the obesity space with GLP-1 drugs, Corbus Pharmaceuticals is betting on a different mechanism. Will its upcoming data rewrite the rules?

Quebec-based Devonian Health Group plans a NYSE American debut, seeking U.S. capital to advance its promising pipeline of autoimmune disease treatments.

With a new FDA nod for its rare disease drug Joenja, Pharming offers hope to young children, signaling a strategic shift in how we treat complex genetic disorders.

A Michigan biotech just patented a way to turn yeast into tiny drug factories inside you. It’s a blueprint for a future without injections or cold chains.

Glucotrack secures $11.5M to fund a breakthrough diabetes monitor, but a look beneath the surface reveals a high-stakes gamble on AI and shareholder value.

A new study reveals an mRNA flu vaccine sustains immune responses for months, a breakthrough that could lead to multi-season protection and end the annual flu shot.

XORTX starts manufacturing its gout drug XORLO™, a pivotal move toward FDA approval. But can it navigate a competitive market and its own financial hurdles?